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Young children on antiretroviral therapy (ART) exhibit superior 
immune reconstitution to adults due partly to high frequencies 
of naïve T cells and preserved thymic function [1]. We report on 
immunological investigations in a child commenced on ART during 
the neonatal period by selecting markers previously associated 
with viraemic control in adults [2–5].
In 2013, a male infant was diagnosed with presumably intrauterine-
acquired HIV [6] (confirmed integrated HIV DNA 1750 copies/106 
peripheral blood mononuclear cells [PBMCs] at age 8 days). The 
infant was initiated on zidovudine/lamivudine/ritonavir-boosted 
lopinavir at age 2 days, and raltegravir (RAL) was added at age 
5 days due to the high HIV RNA load (>10,000,000 copies/mL). 
His HIV DNA at that time was 1750 copies/106 PBMCs [6]. The 
infant’s viral load dropped to <200 copies/mL after 6 months 
and to <50 copies/mL after 12 months of ART. At 18 months, 
while on RAL, lamivudine and abacavir, he lost maternal HIV 
antibodies (non-reactive fourth generation HIV-1/2 assay, Viron-
ostika HIVAg/Ab, BioMérieux, and negative Western blot), indi-
cating low HIV RNA viral burden [7,8]. At that time, he had 
protective antibody titres to hepatitis B virus, tetanus, poliomyelitis, 
diphtheria and pertussis vaccines and normal total immunoglobulin 
levels. His CD4 T lymphocyte count was 2030 cells/mm3 (26%), 
CD4:CD8 ratio was 1.5, HIV RNA was <50 copies/mL and HIV 
DNA was 123 copies/106 PBMCs.
We investigated innate and adaptive immune markers reported to 
be associated with viraemic controllers including elite controllers 
(ECs) and post-treatment controllers (PTCs) in the Visconti cohort 
of adults treated during primary HIV infection and subsequently 
able to control viraemia after treatment interruption [9].
HLA class I and II typing did not show the HLA-B35 and HLA-B07 
alleles seen in PTCs or the HLA-B27 and B57 alleles associated 
with ECs.
There were high frequencies (35%) of activated (HLA-DR+) 
natural killer (NK) cells. Inducibility was low for NKp30 but high 
for NKp44 (1.09 and 103.8, respectively and reported as fold 
change in the proportion of activated NK cells expressing NKp30/
NKp44 after 4 days of in vitro activation with rh-IL2). NK cells 
are activated in adults with untreated HIV [10], and can be 
persistent following successful ART and CD4 immune reconstitu-
tion [11,12]. Persistent NK cell activation is also reported in EC 
adults [5]. The reasons are unclear but could be due to virus 
replication or production in secondary lymphoid tissues with 
insufficient antiretroviral drug concentrations [13].
We analysed the proliferative activity and cytokine profile (per-
centage of antigen-specific IL-2 and IFN-γ producing cells) by 
flow cytometry of CD4 and CD8 T lymphocytes after in vitro 
stimulation with recall antigens: tetanus toxoid (TT), Candida 
albicans (Ca), influenza virus (FLU) and deca-pools of 20mer 
overlapping peptides of HIV retrotranscriptase (RT). There was 
a positive response to recall stimuli in both T cell subsets, and a 
weak response to some peptide deca-pools of RT by CD8 and 
CD4 T lymphocytes. A high frequency of CD4+ IL-2+ cells specific 
for RT peptides was observed in comparison with those for recall 
antigens. There were also low frequencies of CD4+ IFN-γ+ cells 
except for Ca antigens. There were higher frequencies of CD8+ 
IL-2+ cells against pool 1 of RT peptides compared to those 
observed for recall antigens and other RT peptide pools, and low 
levels of CD8+ IFN-γ+ cells, except for Ca antigens. These data 
indicate maintenance of circulating memory CD4+ and CD8+ T 
cells specific for HIV antigens [5,8,14,15].
The frequencies of CD45RA+CCR7+ naïve cells were high on 
both CD4+ and CD8+ T lymphocytes (58% and 43%). The dis-
tribution of antigen-experienced T cells showed: (a) higher per-
centage of CD45RA-CCR7- effector memory (EM) (40%) cells 
compared to CD45RA-CCR7+ central memory (CM) (5%) and 
CD45RA+CCR7- terminally effector memory (TEM) (11%) cells 
on CD8 T cells; (b) similar percentages of CM, EM, TEM popula-
tions on CD4+ (16%, 14% and 11%, respectively) and CD3+CD8- 
T cell subsets (Figure 1a).
Eomes transcription factor expression was evaluated by flow 
cytometry on total CD4+ and CD8+ T lymphocytes: 25% of 
Eomes+ CD8+ T cells (32% T-betlowEomes+, 68% T-bethighEomes+ 
respectively); 64% of Eomes+ cells were CD28+ and 44% were 
CD127+. The data on CD4+ T cells showed: 8% Eomes+ (34% 
T-betlowEomes+ and 66% T-bethighEomes+); 67% of Eomes+ cells 
were CD28+ and 39% were CD127+ (Figure 1b). We observed 
PD-1 expression on 4.4% CD4+ and 8.1% CD8+ T cells. Adults 
with HIV were reported to have a subpopulation of HIV-restricted 
CD8+T-betloEomeshi exhausted T lymphocytes [2]. Our case had 
a profile similar to healthy individuals with a high proportion of 
Eomeshi cells including Eomes+ cells expressing CD127+ and 
CD28+ [4].
The analysis of regulatory T cells (Treg) revealed a normal fre-
quency of CD25highFoxP3+ cells on CD4+ Treg population (5%), 
and no CD8+Treg circulating cells, consistently with an undetect-
able HIV RNA load [16]. The frequency of resting or naïve Treg 
(3% CD45RA+FoxP3low) was higher than those of secreting T 
cells (1.2% CD45RA-FoxP3low) and activated Treg (0.7% CD45RA-
FoxP3high, Figure 1c).
We therefore concluded that early and suppressive ART initiated 
in infancy in this child led to immune preservation of CD4+ and 
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Figure 1. Immunological status at age 18 months in a child who initiated antiretroviral therapy from age 2 days. (a) Evaluation of naïve and central memory (CM), effector memory 
(EM) and terminal effector memory (TEM) populations on CD4+ and CD8+ T cell subsets. (b) Expression of Eomes, T-bet transcription factors and CD28, CD127 markers 
on circulating CD8+ and CD4+ T lymphocytes. (c) Analysis of circulating CD4+ Treg population. Treg: regulatory T cells.
LETTERJournal of Virus Eradication 2019; 5 : 47–49
Immunological profile of a PI-treated infant 49
CD8+ T cells with high frequencies of naïve cells and low expression 
of activation and exhaustion markers. HIV DNA continued to be 
detected. The RAL used in this case may have contributed to the 
rapid plasma viral load decline and immunological recovery. This 
case is an example of an early-treated child who might benefit 
from future immunotherapies to boost HIV-specific immunity.
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